16th April 2003
CELLTECH ANNOUNCES APPOINTMENT OF
NEW CHIEF EXECUTIVE OFFICER
Celltech Group plc today announced the appointment of Dr. Göran Ando (54) as CEO, with immediate effect. Dr. Ando served as President of R&D at Pharmacia Corporation until its acquisition by Pfizer, which completed on 15 April 2003. Dr. Ando’s extensive business role as an Executive Vice President of Pharmacia incorporated responsibility for business development, including mergers and acquisitions, and for manufacturing. Dr. Ando’s previous appointments (summarised in the attached CV) included a period as R&D Director for Glaxo Group Research.
Dr. Ando succeeds Dr. Peter Fellner, who has been CEO of Celltech since 1990. Dr. Fellner will take up the position of Chairman with immediate effect, following the retirement of Mr. John Jackson.
Dr. Fellner commented, “In appointing Dr. Ando as Celltech’s new Chief Executive Officer, we have selected an individual who not only has an exceptional track record in drug discovery and development appropriate for a leading R&D based biotechnology company, but one who also has extensive business experience and capabilities to guide Celltech through its next phase of growth. We are delighted that someone of his stature will be taking up the leadership of Celltech.
Göran and I have worked closely together during the past two years, in the context of Celltech’s landmark partnership with Pharmacia, and he brings to Celltech qualities which I believe will accelerate the Company’s development as a global biotechnology leader”.
The Celltech management team reporting to Dr. Ando will be:
| • | Peter Allen, who is appointed Deputy CEO, with further operational responsibilities, in addition to his continuing role as Chief Financial Officer. | ||
| • | Dr. Melanie Lee, Director of R&D. | ||
| • | Ingelise Saunders, CEO of Celltech Pharmaceuticals. | ||
| • | Peter Nicholls, Group HR Director. |
Dr. Ando commented, “Celltech is a world-leading biotechnology company with an exciting and innovative product pipeline. I am looking forward immensely to working with its management and scientists at this very exciting stage in the company’s development.”
The Board of Celltech thanks Mr. John Jackson for his very valuable contribution as Chairman over a 20 year period, during which Celltech has developed from an early-stage research-based company into one of the largest European biotechnology companies.
Contacts:
| Dr. Peter Fellner,Chairman | (44)(0)1753 534655 | |
| Peter Allen,Deputy CEO and CFO | ||
| Richard Bungay,Director of Corporate Communications | ||
| Jon Coles,Brunswick (London) | (44)(0)207 4045959 | |
| Fiona Fong,Brunswick (London) | (44)(0)207 4045959 | |
| Cindy Leggett-Flynn,Brunswick (New York) | (1)(212)333 3810 |
Celltech Group plc (LSE: CCH; NYSE: CLL) is one of Europe’s largest biotechnology companies, with an extensive late stage development pipeline and a profitable, cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering. More details can be found at www.celltechgroup.com.
Notes for Editors
Dr. Göran Ando - Curriculum vitae
Curriculum Vitae
Dr. Göran A. Ando
Personal Details
| Date of Birth: Marital status: | March 6, 1949 Married (2 children) |
Education
| Saltsjobaden High School, Sweden: Linkoping Medical University: Specialist, General Medicine: | Graduated 1967 Graduated 1973, MD 1978 |
Professional
| 1973 –1977 | House Physician Visby Hospital, Sweden |
| 1978 –1980 | Medical Director Pfizer AB, Sweden | |
| 1980 –1983 | Director Clinical Research, Pfizer International, NY USA | |
| 1983 –1985 | Vice President, Medical & Scientific Affairs Bristol-Myers International Group, NY USA | |
| 1986 – 1989 | Medical Director, promoted to President Astra Research Centre, Sweden | |
| 1989 –1995 | Joined as Medical Director; promoted to Deputy R&D Director, and then R&D Director for Glaxo Group Research. For two years, was also responsible for Product Strategy (= central marketing) group. Managing Director of Glaxo Group Ltd. Member of Group Executive Committee Glaxo Ltd., UK | |
| Executive Vice President & Deputy CEO Pharmacia AB, Sweden | ||
| 1995 – 1997 | Executive Vice President, Worldwide Science & Technology Pharmacia & Upjohn, UK | |
| Chairman Pharmacia & Upjohn AB, Sweden | ||
| 1997 – Present | Executive Vice President and President, Research & Development, with additional responsibility for manufacturing, IT, business development, mergers & acquisitions. Pharmacia Corporation, NJ USA |
Other
Member, Board of Directors
Biotechnology Industry Organization (BIO)
Washington, DC
Member, Board of Directors
Agency of Science, Technology & Research (A*STAR)
Singapore
Chairman of Board (1995-1999)
MorphoSys GmbH
Munich, Germany
Chairman of Board (1996-1999)
Prolifix Limited
London, UK
Chairman of Board (1998-2000)
IntrinsiQ Data Corporation
Boston, MA
Honorary Doctorate in Medicine (awarded 2002)
Karolinska Institute
Stockholm, Sweden
William Pitt Fellow (1997 – present)
Pembroke College
Cambridge University
Founding Fellow
American College of Rheumatology